Plain English Summary
Background and study aims
Irritable bowel syndrome (IBS) is one of the most common disorders of the digestive system in the European population. IBS is part of a group of diseases called functional bowel disorders, and is associated with various symptoms such as abdominal pain, diarrhea, constipation and flatulence. Current treatments are limited to treating these symptoms and so far there is no single therapy used to treat patients. Many of the existing drug therapies are associated with significant side effects. Several studies have stated that in people with IBS, the barrier function of the intestine is compromised, allowing bacteria to pass through it and into the inner most layers of the bowel wall (intestinal mucosa) due to increased intestinal permeability. This movement of bacteria (bacterial translocation) is thought to be responsible for IBS symptoms. Bifidobacteria can stick to cells lining the intestine in groups, forming a natural coating (biofilm). This biofilm can help to improve the barrier function of the intestine, and help alleviating IBS symptoms or induction of remission. Based on the demonstrated in vitro adhesive behavior of heat-inactivated Bifidobacteria bifidum (B. bifidum) to intestinal epithelial cells, the aim of this study is to find out whether taking heat-inactivated B. bifidum FGP-IBS-HI007 is an effective and safe treatment for IBS.
Who can participate?
Adults with IBS.
What does the study involve?
Participants are randomly allocated to one of two groups. Participants in the first group take two capsules a day at mealtimes containing heat-inactivated B. bifidum FGP-IBS-HI007 for eight weeks. Participants in the second group take two placebo (dummy) capsules a day at mealtimes for eight weeks. Participants in both groups attend study visits at the physician two weeks before treatment, at the start of treatment, after four weeks of treatment, after eight weeks of treatment and two weeks after the end of treatment. During these visits, participants have a physical examination (at each visit) and blood samples are collected (at the beginning and at the end of the study). In addition, participants must keep a daily diary at home detailing his/her symptoms over the whole study period.
What are the possible benefits and risks of participating?
Participants taking B. bifidum FGP-IBS-HI007 may benefit from an improvement of their IBS symptoms and quality of life via a safe treatment. Bifidobacteria are generally regarded as safe and in Europe they possess the QPS (qualified presumption of safety) status by the EFSA (European Food Safety Authority) and in the US the GRAS (Generally Recognized as Safe )-status. In addition, the incidence of adverse events in clinical trials with Bifidobacteria is comparable to placebo. The bacteria contained in the test product (B. bifidum FGP-IBS HI007) were isolated from a fecal sample of a healthy person. In addition, the strain is heat inactivated. However, this process does not lead to a release of cell fragments nor does it affect the morphological form of the bacterial cells. Therefore, it can be assumed that the rate of adverse events is no different from ingesting the living bacterial strain. Thus, the risks of this trial are equal to those conventionally associated with ingesting commercial probiotic products, which are considered to be low. Over the course of the blood sampling the usual side effects of blood sampling can occur.
Where is the study run from?
Israelite Hospital in Hamburg (lead centre) and about 25 medical centres in Hamburg and Munich (Germany)
When is study starting and how long is it expected to run for?
September 2015 to December 2016
Who is funding the study?
PharmaFGP GmbH (Germany)
Who is the main contact?
1. Sonja Henneberger (public)
2. Bastian Baasch (scientific)
Ms Sonja Henneberger
Am Haag 14
+49 89 78 79 79 0 -28
Mr Bastian Baasch
Am Haag 14
+49 89 78 79 79 0 -47
Randomised, double-blind, placebo-controlled, multicentre clinical trial for proving the efficacy of heat-inactivated Bifidobacterium bifidum FGP-IBS-HI007 in the treatment of patients with irritable bowel syndrome
The combined responder rate is greater after consumption of FGP-IBS-HI007 than after consumption of placebo.
Ärztekammer Hamburg (Medical Association Hamburg), 18/01/2016 (advisory opinion), ref: PV5163
Multicentre randomised double-blind placebo-controlled clinical trial
Primary study design
Secondary study design
Randomised controlled trial
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet.
Irritable bowel syndrome (IBS)
Participants are block randomised into two groups in a 1:1 ratio.
Treatment group: Participants take two capsules containing heat-inactivated B. bifidum FGP-IBS-HI007 (0,5x10^9 cfu per capsule) per day for 8 weeks.
Control group: Participants take two placebo capsules per day for 8 weeks.
The trial consists of three phases:
1. Run-in phase (2 weeks)
2. Treatment phase (8 weeks)
3. Wash-out phase (2 weeks)
The trial includes five visits per participant at the physician:
1. Before run-in phase (visit 1)
2. After run-in phase and before treatment phase (visit 2)
3. Middle of treatment phase (after 4 weeks of treatment) (visit 3)
4. After treatment phase and before wash out phase (visit 4)
5. After wash-out phase (visit 5)
Primary outcome measures
Response-rate based on adequate relief of IBS symptoms in combination with an improvement in abdominal pain at the end of the treatment phase, adequate relief of IBS symptoms is measured weekly for 10 weeks (during the treatment phase and the wash out phase) using the 7-point Likert scale, abdominal pain is measured daily for 12 weeks using the 11-point numerical rating scale (NRS).
Secondary outcome measures
1. Response-rates of the single parameters of the combined endpoint, adequate relief of IBS symptoms is measured weekly for 10 weeks (during the treatment phase and the wash out phase) using the 7-point Likert scale, abdominal pain is measured daily for 12 weeks using the 11-point numerical rating scale (NRS)
2. Subject’s global assessment of symptoms, measured daily for 12 weeks using the 7-point Likert scale
3. Spontaneous bowel movements (numerically), stool consistency (using the Bristol Stool Form Scale), and feeling of incomplete evacuation (numerically), measured daily for 12 weeks
4. Mucus and blood in stool, measured numerically on a weekly basis for 12 weeks
5. Symptom-free and pain-free days, assessed daily for 12 weeks using the 7-point Likert scale of the subject’s global assessment of symptoms and the 11-point numerical rating scale of abdominal pain measurement
6. Severity of IBS symptoms, measured at visits 2, 3, 4 and 5 using the IBS-severity symptom system (IBS-SSS) score
7. Quality of life, measured at visits 2, 3 and 4 using the SF-12 health survey
8. Safety, using results of vital parameters (measured at visits 1, 2, 3, 4 and 5), blood samples (collected at visits 1 and 5), adverse events (assessed at visits 1, 2, 3, 4 and 5) and subjective assessment of tolerability of the test product via the patient (assessed at visits 3, 4 and 5)
Overall trial start date
Overall trial end date
Participant inclusion criteria
1. Patients with IBS, diagnosed according to the Rome-III-criteria
2. Otherwise healthy male or female subjects, aged between 18 and 65 years
3. Negative result of a sigmoidoscopy or coloscopy within the preceding 5 years for patients above 55 years of age
4. Legal capacity
5. Written consent of the patient
6. Understanding of the German language and compliance
7. Patient has understood, that changes in life style and nutrition habits have to be avoided
8. Patient has understood the principle of the patient-diary and is willing to keep it according to the requirements
9. Negative pregnancy test
Target number of participants
Participant exclusion criteria
1. Inflammatory bowel diseases (Crohn's disease and Ulcerative colitis)
2. Systemic diseases, cancer, autoimmune diseases
3. Known abnormalities in abdomen region e.g. unusual ultrasound that would require further investigation
4. Ingestion of antipsychotics within the last 3 months prior to the start of the study. Ingestion of systemic Corticosteroids wihtin the last month prior to the start of the study.
5. Ingestion of medication influencing the efficacy of the tested product (i.e. analgetics, antibiotics, chemotherapeutics, antipsychotics, laxatives, spasmolytics, antidiarrhoeals)
6. Ingestion of other probiotic products
7. Serious psychiatric disorders within the last 2 years
8. Diabetes mellitus
9. Hyperthyroidism and hypothyroidism
10. Lactose intolerance or other malabsorption syndromes
11. Immune deficiency
12. Abdominal surgeries (exceptions include: appendectomies, hernia surgeries, cholecystectomy, sectio caesarea)
13. Coeliac disease
14. Known positive stool culture for patients with diarrhea-predominant IBS
16. Known parasites or eggs in stool
17. Laboratory abnormalities which would expose the patient to an unacceptable risk or influence intepretation of study data
18. Serious diseases resulting in a need for care, a need for a guardian or resulting in immobilisation
19. Alcohol or drug abuse
20. Pregnancy or lactation period
21. Participation in other interventional trials or participation in other interventional trials within the last 30 days
22. Nonautonomous individuals, not capable of making decisions independently e.g. due to a relationship with a sponsoring party or relationship with a physician, both of whom may be capable of pressuring the participant
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Isrealite Hospital Hamburg
Am Haag 14
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
A manuscript including the data of the trial is intended to be published in a peer reviewed journal.
Intention to publish date
Participant level data
Not expected to be available
Results - basic reporting